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Abstract 
 
This is the first study to evaluate the spectrum and prevalence of dose-predictive genetic 
polymorphisms of the CYP2C9, CYP4F2 and VKORC1 loci together, in a geographically-defined, 
ethnically admixed healthy adult Omani population sharing common life style/environmental factors. 
Since the present day Omani population is the result of an admixture of Caucasian, African and Asian 
ancestries, we compared the pharmacogenetic profile of these three loci in this population. 
Interestingly, the Omani pharmacogenetic profile, in terms of allele and genotype distribution, has 
values that are intermediate between Caucasians and African Americans, the African admixture further 
substantiated by the presence of CYP2C9*8 allele. However, limitations and usefulness of such 
comparisons warrant caution, as the data from pharmacogenetic literature do not always represent 
bonafide population categories. Furthermore, definition of study population based on 
microgeographical scale would be more appropriate in pharmacogenetic research rather than the 
flawed racial, ethnic or social categorizations since pharmacogenetic variation is clinal, and genetic 
influences will be further altered by lifestyle and environmental factors. 
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Introduction 
In the current clinical practice, routine pharmacogenetic testing is performed only for a few 
drugs and an important candidate is warfarin, a commonly prescribed anticoagulant with 
narrow therapeutic index. Small warfarin dose variations result either in hemorrhagic or 
thrombotic complications1. Initially genetic polymorphisms in cytochrome P450 2C9 
[CYP2C9] and vitamin K epoxide reductase complex 1 [VKORC1] have been shown to affect 
the warfarin dose and thereby influence the occurrence of complications1-4. Subsequently, a 
genetic variant of CYP4F2 locus was also found to be associated with warfarin dose 
variability and time to reach therapeutic international normalized ratio (INR) through a linked 
polymorphism5,6. Since the risk of bleeding, due to over-anticoagulation, occurs mainly at the 
initiation of warfarin therapy7, knowledge of a patient’s genotype could be beneficial in 
planning an initiation protocol that is likely to avoid this complication. Accordingly, inclusion 
of CYP2C9, CYP4F2 and VKORC1 genotype data in the existing algorithms is expected to 
reduce the risk of bleeding during the warfarin induction phase. 
 
Nevertheless, most pharmacogenetic models explain less than 50% of the variation in the 
warfarin dose amongst treated patients. This implies that other factors (genetic, concurrent 
disease, or environmental) participate in the intra and inter individual variations in warfarin 
dose requirement. However, three subsequent large genome-wide association studies failed to 
confirm the existence of additional genetic loci, other than CYP2C9, CYP4F2 and VKORC18-
10. Therefore, the unexplained part of the variability is believed to be essentially due to life 
style and environmental factors (including dietary bioavailability of vitamin K).  
 
At the population level, significant differences are reported in the performances of dosing 
algorithms between groups loosely designated as Caucasians and African Americans, with 
only marginal benefit for African Americans during warfarin initiation therapy6,11. Similarly, 
performance was quite variable even within the so called east Asian population groups12. Such 
differences are believed to be due  mainly to significant differences in the prevalence of 
functional polymorphisms in the genes encoding the key enzymes involved in the 
pharmacokinetic(CYP2C9 and CYP4F2) and pharmacodynamic (VKORC1) behavior of 
warfarin/ vitamin K although, as mentioned above,  other non-genetic factors could still 
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contribute to some extent. Given the fact that the frequency distribution of polymorphisms in 
CYP2C9 and VKORC1 varies across populations, influence of these genes could affect 
different proportions of individuals in a given population. Thus a clear understanding of the 
spectrum and prevalence of functionally relevant mutant alleles of these loci in a given 
geographically-restricted population group could help in designing targeted screening 
strategies for markers of drug response. In fact it is striking to note that the present trend in 
labeling populations into ethnicity/race is not accurate and hence does not represent the 
bonafide genetic structure and drug response profiles of a given study population. Moreover, 
since human genetic variation is greatly influenced by geography it is more appropriate to 
study the genetic structuring of geographically–defined populations for evaluating the efficacy 
and safety of drugs with narrow therapeutic index such as warfarin rather than using the 
flawed concepts of (self identified) race/ethnicity. Accordingly, we thus undertook to analyze 
the frequency distribution of warfarin dose-predictive genetic polymorphisms in the VKORC1, 
CYP2C9 and CYP4F2 loci, for the first time, in a geographically defined, ethnically admixed 
Omani population. 
 
Materials & methods 
Study population 
The study was initiated after obtaining formal approval from the institutional ethics 
committee. Study subjects were unrelated healthy adult blood donors attending the blood 
bank at the Sultan Qaboos University Hospital, Muscat, Oman. A written informed consent 
was obtained from each participant as per our study protocol. A total of 240 subjects (180 
males and 60 females) agreed to participate. Their mean age was 28.6(+7.2 SD) years.  
 
A 5ml blood sample was collected in tubes containing EDTA. Genomic DNA was isolated 
using the semi-automated ABI PRISM™ 6100 Nucleic Acid Prep Station, [Applied 
Biosystems, Foster city, CA, USA] and samples were stored at -200C pending analysis. All 
the DNA polymorphisms were studied by direct sequencing of the relevant PCR- amplified 
genome segment on ABI PRISM™ 3100 Genetic Analyzer (Applied Biosystems, Foster city, 
CA, USA) using home-designed primers.[available on request] 
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Genotyping 
CYP2C9 & CYP4F2:  
DNA segments encompassing exons 3 and 7 of CYP2C9 and exon 11 of CYP4F2 genes were 
amplified by PCR and the PCR products were submitted for DNA sequencing to explore the 
following single nucleotide polymorphisms(SNPs); CYP2C9 *2 (430C>T), *3 (1075A>C), 
*4 (1076T>C), *5 (1080C>G), *8(449G>A),*11(1003C>T) and CYP4F2*3(1297G>A) 
respectively using a sequencing protocol provided by the manufacturer of the commercial kit. 
(Applied Biosystems, Foster city, CA, USA) 
 
VKORC1:  
The DNA segment containing the g.-1639G>A polymorphism (rs 9923231) and 6484 C>T or 
g.1173 C>T (rs 9934438) of the VKORC1 locus (GeneBank accession number AY587020) 
were PCR-amplified and analyzed by DNA sequencing of the PCR product as above.  
 
Statistical analysis:  
Frequency distribution of the CYPC2C9, CYP4F2 and VKORC1 polymorphisms were 
compared by chi square and Fishers exact test. A p value of < 0.05 was considered as 
statistically significant. The observed allele frequencies were used in Hardy-Weinberg’s 
equation for analyzing the degree of deviation, if any, between the observed and expected 
genotype frequencies by using weighted least square estimates of allele frequencies and chi-
square goodness-of-fit tests, using SPSS software (ver.15) for all statistical analysis. 
 
Results 
CYP2C9 allele & genotype frequencies 
Amongst a total of 240 subjects enrolled, genetic polymorphisms of CYP2C9, CYP4F2, and 
VKORC1 loci were analyzed in 220,(Table 1) 192(Table 2) and 157(Table 3) samples 
respectively and the combined frequencies for all the three loci was available in 157 
subjects(Table 4). The results obtained in this study were compiled and compared with the 
data reported for the Caucasian, African American and Asian populations6.  The combined 
CYP2C9 mutant allele (CYP2C9 *2,*3 and *8) frequency for Omanis was 0.16, a value 
intermediate between that of Caucasians and African Americans. Similarly, the frequency of 
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warfarin-sensitive homozygotes or compound heterozygotes for the CYP2C9 mutant allele 
was also of intermediate value between Caucasians and African Americans/Asians. The 
CYP2C9 *4, *5, and *11 alleles were not found in the studied Omani subjects [direct 
sequencing of exons 3 and 7].  
 
CYP4F2 allele & genotype frequencies 
The variant allele and genotype frequencies of the CYP4F2 locus are compiled with data for 
Caucasian, African American and Asian populations6. The observed CYP4F2*3 allele and 
genotype frequency in Omanis was not different from that observed in Caucasians/Asians, 
but was quite significantly higher (p<0.05) than that reported for African Americans (3 and 
10 fold respectively).  
 
VKORC1 allele and genotype frequencies 
The frequency of the minor allele g.-1639A in Omanis showed intermediate values between 
African Americans and Caucasians, but nevertheless threefold higher than African 
Americans and around three fourths of the frequency reported in Caucasians6. Nevertheless, 
Asians had the highest frequency of VKORC1 variant allele (1.5 to 2 fold of Caucasians and 
Omanis respectively). A similar trend was noted for the homozygosity for this warfarin 
sensitive VKORC1 allele.  
 
Combined CYP2C9, CYP4F2 and VKORC1 frequencies 
The combined frequency data for the CYP2C9, VKORC1 and CYP4F2 loci which allow the 
prediction of probable outcome if exposed to warfarin6. In these 157 Omani subjects, for 
whom we had the complete data for all the analyzed loci, individual warfarin sensitive 
genotype frequency of CYP2C9 as well as VKORC1 were seen in 3.7% and 14% 
respectively. However, none of these subjects were homozygous for the CYP4F2*3 allele 
(Table 4), which confers relative warfarin resistance5,6. Furthermore, amongst these 157 
subjects, only 2 cases (1.2%) were bearing warfarin-sensitive genotype for both CYP2C9 and 
VKORC1 loci together. 
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Discussion 
This is the first study documenting the frequencies of CYP2C9, CYP4F2, and VKORC1 in 
healthy adult Omani subjects. Oman, is located in the southeastern part of the Arabian 
Peninsula with a native population of around 2 million. The Omani population consists of an 
admixture of Caucasian, African and Asian ancestries. Each of these populations, 
constituting the present day Omanis, had previously been shown to require a distinct average 
warfarin dose corroborating with the relative prevalence of warfarin sensitive alleles. 
 
CYP2C9 
CYP2C9 is the principal drug metabolizing enzyme that catalyzes the hydroxylation of 
warfarin13,14. The CYP2C9 enzyme accounts for 80%–85% of the metabolism of the 
pharmacologically potent S-warfarin enantiomer. Seven principal alleles of CYP2C9, 
including CYP2C9*2 (430C>T), *3 (1075A>C), *5 (1080C>G), *6 (818delA) *8(449G>A) , 
(1003C>T)*11 and (269T>C)*13 (http://www.cypalleles.ki.se)15, are associated with a 
decreased metabolic efficiency of the CYP2C9 enzyme15-17. Although more than 34 different 
CYP2C9 variants have been described, only two common variants, CYP2C9*2 and 
CYP2C9*3 have consistently been shown to be polymorphic in various populations and have 
been demonstrated to show significant clinical variability in warfarin dose requirements with 
propensity for bleeding complications1-3.  
 
Direct sequencing of the two exons of CYP2C9 was our option (instead of RFLP-based 
assessment of the two SNP’s [i.e. CYP2C9*2 and *3] as, by sequencing the exons 3 and 7 of 
the CYP2C9 gene, we were able to study the status of six of the seven principal alleles 
responsible for significant reduction in the enzyme activity namely CYP2C9*2,*3,*5, *6,*8 
and *11 alleles15-18 with  the last four alleles occurring almost exclusively in Africans . This is 
relevant, as the present Omani population is known to have African admixture as Zanzibar 
was under Omani rulers. In our study, we observed that homozygotes and compound 
hetrozygotes for the mutant CYP2C9*2,*3 and *8 alleles were present in about 3.7% of the 
Omani subjects with a heterozygote rate of 24.2% (Table 1) comparable with a previous 
report on Omani patients on warfarin therapy19. However, that study did not explore the 
8 
 
polymorphic state of the VKORC1 and CYP4F2 loci, which are also associated with warfarin 
dose variability. 
 
CYP4F2 
The CYP4F2 locus has been shown to code  the primary human liver microsomal vitamin K1 
oxidase and the CYP4F2*3 allele is associated with decreased steady-state hepatic 
concentrations of the enzyme with consequent reduction in the metabolism of vitamin K1 and 
a higher warfarin requirement for therapeutic anticoagulant effect.  Indeed subjects 
homozygous for CYP4F2*3 allele require warfarin of about 1.2mg more than the wild type 
genotype5. Since CYP4F2*3 allele frequency in African American subjects is distinctly low 
they are believed to benefit less from the dosing algorithms that include this variant6,20. 
Furtheremore, since Omani subjects have a comparable frequency of CYP4F2*3 allele with 
that of Caucasians, its effect in the algorithm will be similar, but quite marginal as we failed 
to find homozygous CYP4F2*3 allele in any of the subjects bearing the warfarin sensitive 
genotype for CYP2C9 and VKORC1(Table 4). On the contrary, we speculate that CYP4F2 
typing will be particularly beneficial for east Asian population given the high frequency of 
both the VKORC1 warfarin sensitive genotype and the relative warfarin resistant CYP4F2 
*3/*3 genotype. 
 
VKORC1 
Some common SNPs of VKORC1 locus defining the VKORC1 haplotypes have been 
associated with clinically significant differences in warfarin maintenance dose3. Indeed a 
single SNP, either g.-1639 G>A in the VKORC1 promoter or g.1173 C>T in intron 1 behaved 
as a tag SNP in distinguishing the warfarin sensitive VKORC1*2 haplotype from the other 
haplotypes3,4,20. Our study revealed that this warfarin sensitive tag-SNP g.-1639A or g.1173T 
was found in approximately 44% of the Omani population, with 14% in homozygous state.  
 
Population Comparison of CYP2C9, VKORC1 and CYP4F2polymorphism 
Genetic polymorphisms in the CYP2C9, VKORC1 and/or CYP4F2 loci are thus far the only 
important genetic determinants for individual warfarin dose variations8,9. As the frequency 
distribution of these polymorphisms in the three genes varies across populations 
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(https://www.pharmgkb.org/), the relative contribution of the CYP2C9, CYP4F2 and 
VKORC1 to the warfarin dose will obviously be different among population groups21. Given 
the extensive admixture of the present-day Omani population with gene flow from (east) 
Africa, Europe and Asia, it is tempting to compare the prevalence data of Omanis with the 
above mentioned population groups (Tables 1-3).  Indeed the allele and genotype distribution 
has values intermediate between Caucasians and African Americans apparently complying 
with the documented Caucasian and African admixture of the Omani population22, and 
noticeably by the presence of CYP2C9*8 allele in Omanis, a prevalent allele in the African 
population. However, limitations and usefulness of these comparisons and interpretations 
warrant caution as the terms Caucasians, African Americans and Asians used in 
pharmacogenetic literature do not represent population genetic categories, but rather a flawed 
concepts of racial, ethnic and social categories quite often self declared.  This is an important 
consideration because human genetic variation is clinal and greatly influenced by 
geography23. Our study concerns a fully characterized distinct geographically-defined Omani 
population group, with unbiased racial, ethnic or social considerations. Indeed, regardless of 
admixture, individuals from this population share common lifestyle / environmental factors, 
which are also important determinants of warfarin dose response besides genetic factors. 
 
GENETIC INTERACTIONS 
It is interesting to note that although genetic polymorphisms in CYP2C9, VKORC1 and/or 
CYP4F2 are important, homozygosity or compound hetrozygosity for the major mutant 
alleles in CYP2C9 [*2 and *3] and VKORC1 [g.-1639AA] contribute to warfarin sensitivity 
whereas, homozygosity for the mutant allele of CYP4F2 [*3] confers relative warfarin 
resistance3-5,10,14. Thus, from a population perspective, the expected contribution of the 
CYP2C9 and VKORC1 on the one hand and CYP4F2 on the other will be opposite in 
determining the warfarin requirement. Indeed, homozygosity for the CYP4F2*3 has 
previously been associated with a relatively higher warfarin dose requirement in the 
Caucasian subjects5. Nevertheless, the population prevalence of homozygosity for the mutant 
allele CYP4F2*3 in all studied Caucasian populations as well as the Omani population being 
similar, influence of this locus across such populations will be similar, leaving the CYP2C9 
and VKORC1 loci as the main warfarin dose predictive markers in the Omani population. 
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This complies with the previous population studies wherein only CYP2C9 and VKORC1 
were found to be the two major loci influencing the warfarin dose requirement8. Recently a 
paper by Limdi NA et al24 concluded that warfarin-dosing algorithm incorporating  VKORC1 
g.-1639G>A improved dose prediction across 3 racial groups namely Asian, Black and white 
subjects recruited across several countries in the cadre of IWPC. It was then concluded that 
although at the population level, the contribution of VKORC1 towards warfarin dose 
requirements is higher in whites than nonwhites, genotype predicts similar dose requirements 
across racial groups.24 
 
In our population, only 1.2% of Omanis showed warfarin sensitive CYP2C9 and VKORC1 
genotypes together and hence were at the highest risk of bleeding complications if exposed to 
warfarin. None of these subjects however possessed the warfarin relative resistance CYP4F2 
genotype (*3/*3). Thus, altogether around one fourth of the Omani subjects are susceptible to 
warfarin treatment- related bleeding complications as compared to one fifth of the 
Caucasians based on the independent homozygosity for CYP2C9 and VKORC1 mutant 
genotypes (Tables 1 & 3).  
 
In conclusion, this study for the first time establishes the allele and genotype frequencies of 
the three main genetic loci that are associated with the pharmacokinetic (CYP2C9 & 
CYP4F2) and pharmacodynamic (VKORC1) variables for warfarin dose variations in a 
geographically explicit manner for the Omani population.  
 
This study represents a resource for warfarin pharmacogenetic variations in a geographically-
defined Arabian Gulf population, namely the Omanis. Since within this Gulf region, the 
history of population migration and the local effective population size differ, results obtained 
herein cannot be directly extrapolated to neighboring populations and requires perspective 
studies with structured sampling at a microgeographic scale25. At the global level, since 
many regions are still underrepresented in pharmacogenetic research, especially those like 
Africa and Asia where high disease burden and diversity prevails, cost-effective and safe 
pharmacologic interventions are needed. 
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Table 1: ALLELE AND GENOTYPE FREQUENCIES FOR CYPC2C9 IN OMANI SUBJECTS AND THEIR 
COMPARISON WITH OTHER POPULATION GROUPS.  
(a) Allele frequencies  
Allèle        Caucasian6[n=106] Omani [n=220] Afr. American6[n=300] Asian6[n=102] 
*1   0.79           0.84  0.87  0.92 
*2   0.15           0.08  0.03  0.03 
*3   0.06           0.07  0.02  0.04 
*8   0.00           0.01  0.05  0.01 
*others   0.00           0.00     0.03    0.00 
Mu   0.21           0.16  0.13  0.08   
(b)Genotype frequencies (+expected %) 
Genotype   
Extensive metaboliser 
*1/*1   66.0(62.1)                72.1(71.1 )        75.7 (75.1)    86.3(84.9) 
 
Intermediate metaboliser 
*1/*2, *1/*3, *1/*8 25.5(33.4) 24.2(26.47 )        22.7(23.1)       11.8#(14.5) 
*others 
 
Poor metaboliser[Warfarin sensitive] 
*2/*2, *2/*3, *3/*3 8.5#(4.4)  3.7( 2.5)                      1.7#(1.0)  2.0#(0.6) 
*others 
 
Key: Mu – Mutant alleles (CYP2C9*2,*3, *8 &*others together), * others – (*4,*5,*6,*11&*13);              
n=Number of subjects.  Data from Ref. no. 6 is used for comparison 
# p<0.05 when compared with Omani subjects. + Predicted Hardy-Weinberg frequencies. 
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Table 2: ALLELE AND GENOTYPE FREQUENCIES FOR CYP4F2 IN NORMAL OMANI CONTROLS 
AND COMPARISON WITH OTHER POPULATION GROUPS. 
(a) Allele frequencies  
Allele    Caucasian6  Omani         Afr. American6     Asian6 
*1        0.66       0.65   0.88         0.70 
*3        0.34       0.35   0.12#         0.30 
(b) Observed Genotype frequencies (+expected %) 
Genotype        Caucasian  Omani (n=192)    Afr. American        Asian 
CYP4F2 *1/*1        42.7 (43.3)      41.0(41.6)  78.0(78) #           48.0(48.3) 
CYP4F2 *1/*3        46.3(45.0)      47.9(45.6)  20.7(20.6)#            42.0(42.4) 
CYP4F2 *3/*3        11.0(11.7)      11.0(12.5)  1.3(1.4)#   9.0(9.3) 
Data Compiled from Ref. No. 6 is used for comparison 
# p<0.05 when compared with Omani subjects.  
+ Predicted Hardy-Weinberg frequencies, n=Number of subjects. 
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Table 3: ALLELE AND GENOTYPE FREQUENCIES FOR VKORC1 IN NORMAL OMANI CONTROLS 
AND COMPARISON WITH OTHER POPULATION GROUPS. 
(a) Allele frequencies for VKORC1 (g.-1639 G>A)  
     Observed frequency  
Allele     Caucasian6 Omani  Afr. American6  Asian6 
-1639 G      0. 594   0. 683       0.892     0.333 
-1639 A      0. 406    0.317       0.108     0.667 
 
(b)Genotype frequencies for VKORC1 (g.-1639 G>A) 
Observed frequency (+expected %) 
Genotype     Caucasian Omani (n=157)     Afr. American      Asian 
G/G      36.8 (35.3)   40.1 (46.6)       80.3 (79.5)     22.5 (11.1) 
G/A      45.3 (48.2)   45.9 (43.3)       17.7 (19.3)     21.6 (44.4) 
A/A[Warfarin sensitive]    17.9 (16.5)    14.0 (10.1)       2.0 (1.2)     55.9 (44.4) 
 
Data Compiled from Ref. No. 6 is used for comparison 
+ Predicted Hardy-Weinberg frequencies, n=Number of subjects. 
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Table 4: COMPARATIVE POPULATION FREQUENCIES FOR CYP2C9, VKORC1 g.-1639G>A AND 
CYP4F2*3 GENOTYPE  
CYP2C9 VKORC1 CYP4F2*3 #Caucasian Omani [n=157] #Amer. African #Asian 
  g.-1639G>A c.1297G>A Freq. (%) Freq. (%) Freq. (%)  Freq. (%)    
 
Extensive G/G  G/G  12.3  13.4  47.5  4.9 
Metabolizer   G/A  9.4  12.1  11.2  3.9      
    A/A  0.0  0.0  0.7  3.9 
 
  G/A  G/G  11.3  11.5  10.9  10.8  
    G/A  16.0  19.1  4.0  6.9 
    A/A  3.8  1.9  0.0  1.0 
 
  A/A  G/G  5.7  4.5  0.7  26.5 
    G/A  5.7  4.5  0.7  21.6 
    A/A  1.9  1.9  0.0  6.9 
Total      66.1  72.1  75.7  86.4 
 
Intermediate G/G  G/G  4.7  7.0  15.9  3.9 
Metabolizer   G/A  4.7  3.2  4.0  2.0 
    A/A  0.9  0.6  0.4  2.0 
 
  G/A  G/G  3.8  4.5  2.5  2.0 
    G/A  5.7  5.7  0.4  0.0 
    A/A  0.9  1.3  0.0  1.0 
 
  A/A  G/G  1.9  0.0  0.7  0.0 
    G/A  2.8  1.9  0.0  1.0 
    A/A  0.0  0.0  0.0  0.0 
Total       25.4  24.2  23.9  11.9 
 
Poor  G/G  G/G  0.9  0.0  0.0  1.0 
Metabolizer   G/A  3.8  0.6  0.0  1.0 
    A/A  0.0  0.0  0.0  0.0 
 
  G/A  G/G  2.8  0.6  0.4  0.0 
    G/A  0.9  1.3  0.0  0.0 
    A/A  0.0  0.0  0.0  0.0 
 
  A/A  G/G  0.0  0.6  0.0  0.0 
    G/A  0.0  0.6  0.0  0.0 
    A/A  0.0  0.0  0.0  0.0 
Total      8.4  3.7  0.4  2.0 
Extensive metabolizer: CYP2C9*1/*1;                                                                                                          
Intermediate metabolizer: CYP2C9*1/variant;                                                                                                       
Poor metabolizer: CYP2C9 variant/variant 
#Data combined from ref No 6 is used for comparison; n = number of subjects. 
